Sanofi (NASDAQ:SNY) Receives $53.00 Average PT from Brokerages

Sanofi (NASDAQ:SNY) has been assigned an average rating of “Buy” from the eight analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $53.00.

SNY has been the topic of a number of research analyst reports. Morgan Stanley reissued an “overweight” rating on shares of Sanofi in a research report on Friday, August 6th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Sanofi in a research report on Friday, July 30th. Finally, UBS Group restated a “buy” rating on shares of Sanofi in a report on Thursday, August 12th.

NASDAQ SNY traded up $0.18 during trading hours on Thursday, reaching $48.19. The company’s stock had a trading volume of 1,057,715 shares, compared to its average volume of 1,980,032. The firm has a fifty day simple moving average of $51.31 and a 200-day simple moving average of $51.21. The stock has a market cap of $121.51 billion, a P/E ratio of 17.52, a P/E/G ratio of 1.38 and a beta of 0.56. Sanofi has a 52 week low of $44.76 and a 52 week high of $54.26. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.54 and a quick ratio of 1.06.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 29th. The company reported $0.83 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.79 by $0.04. The firm had revenue of $10.53 billion for the quarter, compared to the consensus estimate of $10.29 billion. Sanofi had a net margin of 16.02% and a return on equity of 24.31%. On average, research analysts expect that Sanofi will post 3.85 earnings per share for the current year.

In other news, major shareholder Sanofi bought 66,667 shares of the firm’s stock in a transaction dated Monday, August 2nd. The stock was purchased at an average price of $15.00 per share, with a total value of $1,000,005.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.00% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE increased its holdings in Sanofi by 9.2% in the 2nd quarter. Bank of America Corp DE now owns 9,924,840 shares of the company’s stock worth $522,643,000 after acquiring an additional 833,701 shares in the last quarter. Parametric Portfolio Associates LLC grew its holdings in Sanofi by 8.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 3,013,083 shares of the company’s stock valued at $158,669,000 after buying an additional 222,158 shares in the last quarter. Sawtooth Solutions LLC grew its holdings in Sanofi by 22.3% during the 2nd quarter. Sawtooth Solutions LLC now owns 23,335 shares of the company’s stock valued at $1,229,000 after buying an additional 4,250 shares in the last quarter. Integral Health Asset Management LLC bought a new position in shares of Sanofi during the 2nd quarter valued at approximately $9,216,000. Finally, EP Wealth Advisors LLC bought a new position in shares of Sanofi during the 2nd quarter valued at approximately $356,000. 8.02% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.

Featured Article: Dividend Yield

Analyst Recommendations for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.